A Phase 1/2 interventional study of LM-364 for injection and Tislelizumab in Malignant Tumors, sponsored by LaNova Medicines Limited. Not yet recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors.
For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.
10,837 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.
This study's planned enrollment of 90 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LM-364 for injection
Drug: LM-364 for injection · Drug: Tislelizumab
Q3W, Intravenous Drip
Q3W, Intravenous Drip
Incidence of dose-limiting toxicity (DLT)
Phase I
Time frame: 78 weeks
Incidence of Treatment-Emergent Adverse Events (AEs)
Phase I
Time frame: 78 weeks
Incidence of serious adverse events (SAEs)
Phase I
Time frame: 78 weeks
Temperature (Celsius)
Phase I
Time frame: 78 weeks
Pulse in BPM(Beat per Minute)
Phase I
Time frame: 78 weeks
Blood Pressure in mmHg
Phase I
Time frame: 78 weeks
Weight in Kg
Phase I
Time frame: 78 weeks
Height in centimeters
Phase I
Time frame: 78 weeks
Blood Routine examination -> Complete Blood Count
Phase I
Time frame: 78 weeks
Urine Routine examination ->Urinalysis
Phase I
Time frame: 78 weeks
Blood Biochemistry test -> Electrolytes and Metabolic Parameters
Phase I
Time frame: 78 weeks
Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT),
Phase I
Time frame: 78 weeks
Pregnancy test
Phase I
Time frame: 78 weeks
Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)
Phase I
Time frame: 78 weeks
Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentage
Phase I
Time frame: 78 weeks
12-lead electrocardiogram (ECG) in HR
Phase I
Time frame: 78 weeks
12-lead electrocardiogram (ECG) in RR
Phase I
Time frame: 78 weeks
12-lead electrocardiogram (ECG) in QRS
Phase I
Time frame: 78 weeks
12-lead electrocardiogram (ECG) in QT
Phase I
Time frame: 78 weeks
12-lead electrocardiogram (ECG) in QTcF
Phase I
Time frame: 78 weeks
ECOG(Eastern Cooperative Oncology Group) score
Phase I
Time frame: 78 weeks
Objective Response Rate (ORR)
Phase II
Time frame: 130 weeks
Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)
Phase I/II
Time frame: 130 weeks
PK Parameter:Time of Maximum Observed Concentration (Tmax)
Phase I/II
Time frame: 130 weeks
PK Parameter: Area Under the Concentration-time Curve (AUC)
Phase I/II
Time frame: 130 weeks
PK Parameter: Steady State Maximum Concentration (Cmax,ss) PK Parameter: Steady State Maximum Concentration(Cmax,ss)
Phase I/II
Time frame: 130 weeks
PK Parameter: Steady State Minimum Concentration (Cmin,ss)
Phase I/II
Time frame: 130 weeks
PK Parameter: Systemic Clearance at Steady State (CLss)
Phase I/II
Time frame: 130 weeks
PK Parameter: Accumulation Ratio (Rac)
Phase I/II
Time frame: 130 weeks
PK Parameter: Elimination Half-life (t1/2)
Phase I/II
Time frame: 130 weeks
PK Parameter: Volume of Distribution at Steady-State (Vss)
Phase I/II
Time frame: 130 weeks
PK Parameter: Degree of Fluctuation (DF)
Phase I/II
Time frame: 130 weeks
Immunogenicity testing->Anti-Drug Antibody test
Phase I/II
Time frame: 130 weeks
Objective Response Rate (ORR)
Phase I/II
Time frame: 130 weeks
Duration of Response (DOR) in Month
Phase I/II
Time frame: 130 weeks
Disease control rate (DCR) in percentage
Phase I/II
Time frame: 130 weeks
Progression-free survival (PFS) in Month
Phase I/II
Time frame: 130 weeks
Overall survival (OS) in Month
Phase I/II
Time frame: 130 weeks
Changes of target lesions from baseline in Millimeter
Phase I/II
Time frame: 130 weeks
Incidence of adverse events (AEs)
Phase II
Time frame: 130 weeks
Incidence of serious adverse events (SAEs)
Phase II
Time frame: 130 weeks
Temperature (Celsius)
Phase II
Time frame: 130 weeks
Pulse in BPM(Beat per Minute)
Phase II
Time frame: 130 weeks
Blood Pressure in mmHg
Phase II
Time frame: 130 weeks
Weight in Kg
Phase II
Time frame: 130 weeks
Height in centimeters
Phase II
Time frame: 130 weeks
Blood Routine examination -> Complete Blood Count
Phase II
Time frame: 130 weeks
Urine Routine examination ->Urinalysis
Phase II
Time frame: 130 weeks
Blood Biochemistry test -> Electrolytes and Metabolic Parameters
Phase II
Time frame: 130 weeks
Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalized ratio (INR)
Phase II
Time frame: 130 weeks
Pregnancy test
Phase II
Time frame: 130 weeks
Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free
Phase II
Time frame: 130 weeks
Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentage
Phase II
Time frame: 130 weeks
ECOG(Eastern Cooperative Oncology Group) score
Phase II
Time frame: 130 weeks
12-lead electrocardiogram (ECG) in HR
Phase II
Time frame: 130 weeks
12-lead electrocardiogram (ECG) in RR
Phase II
Time frame: 130 weeks
12-lead electrocardiogram (ECG) in PR
Phase II
Time frame: 130 weeks
12-lead electrocardiogram (ECG) in QRS
Phase II
Time frame: 130 weeks
12-lead electrocardiogram (ECG) in QT
Phase II
Time frame: 130 weeks
12-lead electrocardiogram (ECG) in QTcF
Phase II
Time frame: 130 weeks
Biomarker test -> Tumor tissue biomarker test
Phase I/II
Time frame: 130 weeks
QTc-PK relationship -> Correlation concentrations (total antibody, free DXd) vs ΔQTcF (Fridericia's correction)
Phase I
Time frame: 12 weeks
Start is estimated for Jul 2026; primary completion for Dec 2028, 29 months later.
Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 29 months is below that.
Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.